Abstract
The perivascular sensory nerve (PvN) Ca(2+)-sensing receptor (CaR) is implicated in Ca(2+)-induced relaxation of isolated, phenylephrine (PE)-contracted mesenteric arteries, which involves the vascular endogenous cannabinoid system. We determined the effect of inhibition of diacylglycerol (DAG) lipase (DAGL), phospholipase A(2) (PLA(2)), and cytochrome P-450 (CYP) on Ca(2+)-induced relaxation of PE-contracted rat mesenteric arteries. Our findings indicate that Ca(2+)-induced vasorelaxation is not dependent on the endothelium. The DAGL inhibitor RHC 802675 (1 microM) and the CYP and PLA(2) inhibitors quinacrine (5 microM) (EC(50): RHC 802675 2.8 +/- 0.4 mM vs. control 1.4 +/- 0.3 mM; quinacrine 4.8 +/- 0.4 mM vs. control 2.0 +/- 0.3 mM; n = 5) and arachidonyltrifluoromethyl ketone (AACOCF(3), 1 microM) reduced Ca(2+)-induced relaxation of mesenteric arteries. Synthetic 2-arachidonoylglycerol (2-AG) and glycerated epoxyeicosatrienoic acids (GEETs) induced concentration-dependent relaxation of isolated arteries. 2-AG relaxations were blocked by iberiotoxin (IBTX) (EC(50): control 0.96 +/- 0.14 nM, IBTX 1.3 +/- 0.5 microM) and miconazole (48 +/- 3%), and 11,12-GEET responses were blocked by IBTX (EC(50): control 55 +/- 9 nM, IBTX 690 +/- 96 nM) and SR-141716A. The data suggest that activation of the CaR in the PvN network by Ca(2+) leads to synthesis and/or release of metabolites of the CYP epoxygenase pathway and metabolism of DAG to 2-AG and subsequently to GEETs. The findings indicate a role for 2-AG and its metabolites in Ca(2+)-induced relaxation of resistance arteries; therefore this receptor may be a potential target for the development of new vasodilator compounds for antihypertensive therapy.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
8,11,14-Eicosatrienoic Acid / metabolism
-
Acetylcholine / pharmacology
-
Animals
-
Arachidonic Acids / metabolism*
-
Arachidonic Acids / pharmacology
-
Calcium / metabolism*
-
Cytochrome P-450 Enzyme Inhibitors
-
Cytochrome P-450 Enzyme System / metabolism*
-
Dose-Response Relationship, Drug
-
Endocannabinoids
-
Enzyme Inhibitors / pharmacology
-
Glycerides / metabolism*
-
Lipoprotein Lipase / antagonists & inhibitors
-
Lipoprotein Lipase / metabolism
-
Male
-
Mesenteric Arteries / drug effects
-
Mesenteric Arteries / enzymology
-
Mesenteric Arteries / metabolism*
-
Miconazole / pharmacology
-
Peptides / pharmacology
-
Phenylephrine / pharmacology
-
Phospholipase A2 Inhibitors
-
Phospholipases A2 / metabolism
-
Piperidines / pharmacology
-
Potassium Channel Blockers / pharmacology
-
Potassium Channels, Calcium-Activated / antagonists & inhibitors
-
Potassium Channels, Calcium-Activated / metabolism
-
Pyrazoles / pharmacology
-
Quinacrine / pharmacology
-
Rats
-
Rats, Wistar
-
Receptor, Cannabinoid, CB1 / antagonists & inhibitors
-
Receptor, Cannabinoid, CB1 / metabolism
-
Receptors, Calcium-Sensing / metabolism*
-
Rimonabant
-
Signal Transduction* / drug effects
-
Vasoconstrictor Agents / pharmacology
-
Vasodilation*
-
Vasodilator Agents / pharmacology
Substances
-
Arachidonic Acids
-
Cytochrome P-450 Enzyme Inhibitors
-
Endocannabinoids
-
Enzyme Inhibitors
-
Glycerides
-
Peptides
-
Phospholipase A2 Inhibitors
-
Piperidines
-
Potassium Channel Blockers
-
Potassium Channels, Calcium-Activated
-
Pyrazoles
-
Receptor, Cannabinoid, CB1
-
Receptors, Calcium-Sensing
-
Vasoconstrictor Agents
-
Vasodilator Agents
-
arachidonyltrifluoromethane
-
Phenylephrine
-
iberiotoxin
-
Miconazole
-
glyceryl 2-arachidonate
-
Cytochrome P-450 Enzyme System
-
Lipoprotein Lipase
-
Phospholipases A2
-
8,11,14-Eicosatrienoic Acid
-
Quinacrine
-
Acetylcholine
-
Rimonabant
-
Calcium